As leaders in cardiology, the physicians at Carient are committed to continuing their education and growing their understanding of the best practices and treatments. Often, this new knowledge comes about through clinical research, which is why our team at Carient is dedicated to conducting and participating in research protocols. The insights revealed through clinical research will enable our patients to obtain the newest treatments before they are available to the general public. Carient is one of the few sites in Northern Virginia that participates in large cardiovascular clinical trials that are otherwise only available to major academic centers.

Carient’s physicians are honored to participate in vital and impactful clinical research in the field of cardiology. This research ultimately leads to new advancements in the care we provide our patients. We have been one of only a few sites elected to participate in several elite research studies and new interventional devices and procedures.

The Clinical Research Institute at Carient was established in 2010 under the supervision of Dr. Hamid Taheri. We have participated in over 25 large clinical trials. Our patients have access to new treatments and we have been recognized nationally for our successful enrollment.

We are currently accepting new patients into the following studies:

EMPEROR

The main purpose of the study is to determine the effectiveness of Empagliflozin vs. Placebo, added to best usual treatment, for patients with Chronic Heart Failure and preserved ejection fraction (HFpEF).

INVESTED

Influenza infection is known to be associated with increased risk of cardiovascular (CV) events. INVESTED is a large multi-center trial to access the cardiopulmonary benefit of high-dose compared with standard-dose influenza vaccine in a high-risk cardiovascular population.

PARADISE MI

The purpose of this study is to evaluate the efficiency and safety of LCZ696 compared to Ramipril in addition to conventional post – AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post – AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF.

PROMINENT

The purpose of this study is to evaluate if K-877 (also called pemafibrate, the study medication) compared to placebo lowers cardiovascular events such as heart attack, stroke, and death from these conditions in adults with type-2 diabetes mellitus who have elevated triglycerides and low high-density lipoprotein cholesterol. The study will also test whether the study drug has other possible benefits in diabetic patients.

ORION

The purpose of this study is to evaluate if an investigational drug called inclisiran, which lowers bad (LDL) cholesterol in the blood, will lower the number of cardiovascular events (heart attacks, strokes) in people with pre-existing cardiovascular disease.

Please contact us for more information or if you are interested in participating in a study. Your cardiologist can also speak to you more about being a candidate for a research study during your office visit.
703-335-8750 x-1173.